A new study from the Office of Health Economics (OHE) confirmed that the EQ-5D, a tool commonly used in health technology assessments (HTAs) often excludes outcomes important to patients and their caregivers who rely on treatments for multiple sclerosis, Alzheimer’s disease and sickle cell disease.
